icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
aULnwuprdLuWA52J